• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Ruxolitinib for chronic neutrophilic leukemia: a case report and literature review].

作者信息

Hu N B, Fang L W, Qin T J, Xiao Z J, Xu Z F

机构信息

State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2018 Dec 14;39(12):1029-1032. doi: 10.3760/cma.j.issn.0253-2727.2018.12.012.

DOI:10.3760/cma.j.issn.0253-2727.2018.12.012
PMID:30612407
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7348221/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d262/7348221/b533ee3f0eff/cjh-39-12-1029-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d262/7348221/b533ee3f0eff/cjh-39-12-1029-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d262/7348221/b533ee3f0eff/cjh-39-12-1029-g001.jpg

相似文献

1
[Ruxolitinib for chronic neutrophilic leukemia: a case report and literature review].[芦可替尼治疗慢性中性粒细胞白血病：一例报告及文献综述]
Zhonghua Xue Ye Xue Za Zhi. 2018 Dec 14;39(12):1029-1032. doi: 10.3760/cma.j.issn.0253-2727.2018.12.012.
2
Anti-inflammatory effects of ruxolitinib on chronic neutrophilic leukemia harboring T618I mutation with bilateral renal abscesses.鲁索替尼对伴有双侧肾脓肿的T618I突变慢性中性粒细胞白血病的抗炎作用。
Leuk Res Rep. 2022 Sep 6;18:100348. doi: 10.1016/j.lrr.2022.100348. eCollection 2022.
3
Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.芦可替尼治疗慢性中性粒细胞白血病和不典型慢性髓性白血病患者的疗效。
J Clin Oncol. 2020 Apr 1;38(10):1006-1018. doi: 10.1200/JCO.19.00895. Epub 2019 Dec 27.
4
[Ruxolitinib in the treatment of two cases of chronic neutrophilic leukemia].
Zhonghua Zhong Liu Za Zhi. 2020 Feb 23;42(2):113-114. doi: 10.3760/cma.j.issn.0253-3766.2020.02.005.
5
Successful Allogeneic Stem Cell Transplantation with Ruxolitinib Maintenance Therapy for Mutant Chronic Neutrophilic Leukemia.芦可替尼维持治疗成功用于异基因干细胞移植治疗突变型慢性中性粒细胞白血病
Turk J Haematol. 2023 Feb 28;40(1):73-74. doi: 10.4274/tjh.galenos.2022.2022.0400. Epub 2022 Dec 13.
6
Chronic neutrophilic leukemia, a rare case of leukocytosis.慢性嗜中性粒细胞白血病，一种罕见的白细胞增多症病例。
Leuk Res. 2020 Jul;94:106384. doi: 10.1016/j.leukres.2020.106384. Epub 2020 May 15.
7
[Chronic neutrophilic leukemia/chronic eosinophilic leukemia].[慢性嗜中性粒细胞白血病/慢性嗜酸性粒细胞白血病]
Rinsho Ketsueki. 2023;64(10):1326-1334. doi: 10.11406/rinketsu.64.1326.
8
Chronic neutrophilic leukemia--report of a case and review of the literature.慢性中性粒细胞白血病——一例报告并文献复习
Zhonghua Yi Xue Za Zhi (Taipei). 1990 Aug;46(2):109-12.
9
Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.鲁索替尼治疗CSF3R T618突变型慢性中性粒细胞白血病的临床反应。
Ann Hematol. 2016 Jun;95(7):1197-200. doi: 10.1007/s00277-016-2664-4. Epub 2016 Apr 11.
10
Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.一名CSF3R-T618I阳性非典型慢性髓性白血病患者对JAK1/2抑制有显著临床反应。
Leuk Res Rep. 2014 Aug 1;3(2):67-9. doi: 10.1016/j.lrr.2014.07.002. eCollection 2014.

引用本文的文献

1
Research progress of additional pathogenic mutations in chronic neutrophilic leukemia.慢性中性粒细胞白血病中附加致病性突变的研究进展。
Ann Hematol. 2024 Aug;103(8):2591-2600. doi: 10.1007/s00277-023-05550-6. Epub 2023 Nov 22.

本文引用的文献

1
Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent mutations in chronic neutrophilic leukemia.芦可替尼是一种有效的JAK1/JAK2抑制剂，可使慢性嗜中性粒细胞白血病中并发突变的等位基因负担暂时降低。
Haematologica. 2017 Jun;102(6):e238-e240. doi: 10.3324/haematol.2017.163790. Epub 2017 Mar 16.
2
Changes in allele frequencies of and mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib.使用鲁索替尼治疗的慢性嗜中性粒细胞白血病患者中JAK2和CALR突变的等位基因频率变化及克隆进化证据
Haematologica. 2017 May;102(5):e207-e209. doi: 10.3324/haematol.2016.163089. Epub 2017 Feb 16.
3
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
4
Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.鲁索替尼治疗CSF3R T618突变型慢性中性粒细胞白血病的临床反应。
Ann Hematol. 2016 Jun;95(7):1197-200. doi: 10.1007/s00277-016-2664-4. Epub 2016 Apr 11.
5
ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.ASXL1 突变在 CSF3R 突变的慢性中性粒细胞白血病中频繁发生且具有预后不良影响。
Am J Hematol. 2015 Jul;90(7):653-6. doi: 10.1002/ajh.24031.
6
[CSF3R, ASXL1,SETBP1, JAK2 V617F and CALR mutations in chronic neutrophilic leukemia].慢性嗜中性粒细胞白血病中的CSF3R、ASXL1、SETBP1、JAK2 V617F和CALR突变
Zhonghua Xue Ye Xue Za Zhi. 2014 Dec;35(12):1069-73. doi: 10.3760/cma.j.issn.0253-2727.2014.12.005.
7
Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib.伴有CSF3R T618I和SETBP1突变且对JAK抑制剂芦可替尼无反应的非典型慢性髓系白血病。
Ann Hematol. 2015 May;94(5):879-80. doi: 10.1007/s00277-014-2272-0. Epub 2014 Dec 11.
8
CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia.慢性嗜中性粒细胞白血病中的CSF3R、SETBP1和CALR突变
J Hematol Oncol. 2014 Oct 15;7:77. doi: 10.1186/s13045-014-0077-1.
9
Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.一名CSF3R-T618I阳性非典型慢性髓性白血病患者对JAK1/2抑制有显著临床反应。
Leuk Res Rep. 2014 Aug 1;3(2):67-9. doi: 10.1016/j.lrr.2014.07.002. eCollection 2014.
10
Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib.伴有CSF3R和SETBP1基因突变的慢性嗜中性粒细胞白血病：单克隆集落克隆性研究、对JAK抑制剂的体外敏感性及对鲁索替尼治疗无反应
Leukemia. 2014 Jun;28(6):1363-5. doi: 10.1038/leu.2014.39. Epub 2014 Jan 21.